These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8601556)

  • 1. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 2. If a patient does not respond to a full dose of fluvoxamine for at least 12 weeks, what alternatives should be considered?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549254
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined SSRI-moclobemide treatment of psychiatric illness.
    Joffe RT; Bakish D
    J Clin Psychiatry; 1994 Jan; 55(1):24-5. PubMed ID: 8294388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment.
    Ravindran AV; Griffiths J; Merali Z; Anisman H
    Psychosom Med; 1995; 57(6):555-63. PubMed ID: 8600482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine for psychosis in Alzheimer's disease.
    Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I
    J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB; Fyer AJ; Davidson JR; Pollack MH; Wiita B
    Am J Psychiatry; 1999 May; 156(5):756-60. PubMed ID: 10327910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled withdrawal of selective serotonin reuptake inhibitors in elderly patients in nursing homes with no indication of depression--a commentary.
    Merlo J; Gullberg B
    Eur J Clin Pharmacol; 2005 Jun; 61(4):321-3; author reply 325-6. PubMed ID: 15918058
    [No Abstract]   [Full Text] [Related]  

  • 12. Early augmentation of sertraline with methylphenidate.
    Postolache TT; Rosenthal RN; Hellerstein DJ; Aromin R; Kelton GM; Muran JC; Londono JH
    J Clin Psychiatry; 1999 Feb; 60(2):123-4. PubMed ID: 10084641
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.
    Martin A; Koenig K; Anderson GM; Scahill L
    J Autism Dev Disord; 2003 Feb; 33(1):77-85. PubMed ID: 12708582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
    Zohar J; Keegstra H; Barrelet L
    Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction.
    Banov MD
    J Clin Psychiatry; 1999 Dec; 60(12):866-8. PubMed ID: 10665636
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
    Chengappa KN; Kambhampati RK; Perkins K; Nigam R; Anderson T; Brar JS; Vemulapalli HK; Atzert R; Key P; Kang JS; Levine J
    J Clin Psychiatry; 2001 Jul; 62(7):503-8. PubMed ID: 11488359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
    Joffe RT; Schuller DR
    J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic action and efficiency of fevarin (fluvoxamine) in patients with non-psychotic anxious and apathic-adynamic depressions].
    Neznamov GG; Siuniakov SA; Teleshova ES; Dorofeeva OA; Chumakov DB; Davydova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):19-24. PubMed ID: 11552628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.